Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? - Authors' reply.
作者信息
Udwadia Zarir, Balsari Satchit, Ghafur Abdul
机构信息
Department of Pulmonary Medicine, P.D. Hinduja Hospital and Medical Research Center, Mumbai, India; Department of Pulmonary Medicine, Breach Candy Hospitals & Research Centers, Mumbai, India.
Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, and Global Health and Population Department, Harvard TH Chan School of Public Health, Harvard University, Cambridge, MA02215, USA.
出版信息
Lancet Infect Dis. 2021 Oct;21(10):1350. doi: 10.1016/S1473-3099(21)00480-1. Epub 2021 Aug 24.
Abstract
摘要
相似文献
1
Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? - Authors' reply.
Lancet Infect Dis. 2021 Oct;21(10):1350. doi: 10.1016/S1473-3099(21)00480-1. Epub 2021 Aug 24.
2
Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India?
Lancet Infect Dis. 2021 Oct;21(10):1349-1350. doi: 10.1016/S1473-3099(21)00450-3. Epub 2021 Aug 24.
3
Gastrointestinal services in India during COVID-19: does governance matter? - Authors' reply.
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):692-693. doi: 10.1016/S2468-1253(21)00259-4.
4
Outcomes in neonates born to mothers with COVID-19 during the second wave in India.
Eur J Pediatr. 2022 Sep;181(9):3537-3543. doi: 10.1007/s00431-022-04546-0. Epub 2022 Jul 8.
5
Previous SARS-CoV-2 Infection Status Among the Current RT-PCR-Positive Individuals Affected During the Second Wave of COVID-19 Infections in Chennai, India.
Front Public Health. 2022 Apr 4;10:836454. doi: 10.3389/fpubh.2022.836454. eCollection 2022.
6
Second wave of COVID-19 in India: Dissection of the causes and lessons learnt.
Travel Med Infect Dis. 2021 Sep-Oct;43:102126. doi: 10.1016/j.tmaid.2021.102126. Epub 2021 Jun 16.
7
Containment strategies for COVID-19 in India: lessons from the second wave.
Expert Rev Anti Infect Ther. 2022 Jun;20(6):829-835. doi: 10.1080/14787210.2022.2036605. Epub 2022 Feb 7.
8
India grapples with second wave of COVID-19.
Lancet Microbe. 2021 Jun;2(6):e238. doi: 10.1016/S2666-5247(21)00123-3. Epub 2021 Jun 2.
9
Authors' response.
Indian J Med Res. 2020;152(1 & 2):120. doi: 10.4103/0971-5916.290073.
10
Authors' response.
Indian J Med Res. 2020;152(1 & 2):132-133. doi: 10.4103/0971-5916.292371.
本文引用的文献
1
Ivermectin for preventing and treating COVID-19.
Cochrane Database Syst Rev. 2021 Jul 28;7(7):CD015017. doi: 10.1002/14651858.CD015017.pub2.
2
Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India.
Lancet Infect Dis. 2021 Jul;21(7):905-907. doi: 10.1016/S1473-3099(21)00329-7. Epub 2021 Jun 8.
3
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Sci Rep. 2021 May 26;11(1):11022. doi: 10.1038/s41598-021-90551-6.
4
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
JAMA. 2021 Apr 13;325(14):1426-1435. doi: 10.1001/jama.2021.3071.
5
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Int J Infect Dis. 2021 Feb;103:62-71. doi: 10.1016/j.ijid.2020.11.142. Epub 2020 Nov 16.
Zotero 插件